Dental Considerations in Children with Inherited Bleeding Disorders and Inhibitors: A Systematic Review
2024

Dental Care for Kids with Bleeding Disorders

Sample size: 13 publication Evidence: moderate

Author Information

Author(s): Sanja Vujkov, Branislav Bajkin, Duška Blagojević, Isidora Nešković, Jelena Komšić, Ana Tadić, Bojan Petrović

Primary Institution: Faculty of Medicine, University of Novi Sad, Serbia

Hypothesis

This systematic review evaluates the effectiveness of various hematological treatment protocols and local hemostatic measures in preventing oral bleeding and other complications during and after dental treatments in children with inherited bleeding disorders and inhibitors.

Conclusion

The review highlights the need for standardized protocols that integrate new prophylactic treatments such as Emicizumab to reduce bleeding complications during dental procedures.

Supporting Evidence

  • Emicizumab has significantly shifted the treatment paradigm for children with inherited bleeding disorders and inhibitors.
  • The prophylactic use of Emicizumab has been associated with a marked reduction in the frequency of bleeding episodes.
  • Fewer hospital admissions for bleeding management were reported among patients treated with Emicizumab.
  • Enhanced participation in daily activities was noted in children receiving Emicizumab treatment.

Takeaway

This study looks at how to help kids with bleeding disorders have safer dental treatments. It found that using new medicines can help stop bleeding better.

Methodology

The study was a systematic review that included a comprehensive search across five databases for relevant literature published from January 2000 to February 2024.

Potential Biases

Potential selection and reporting biases were identified, which may affect the interpretation of the findings.

Limitations

The review faced limitations such as a small number of studies, limited diversity in study populations, and potential publication bias.

Participant Demographics

The studies included 13 pediatric patients, with 11 diagnosed with severe hemophilia A and 2 with type 3 von Willebrand disease, all having inhibitors.

Digital Object Identifier (DOI)

10.3390/jcm13247743

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication